The expanding horizon of anti-IL-36 therapy

The IL-36 signaling pathway dermatology revolution is underway. This pathway is key in the pathogenesis of generalized pustular psoriasis (GPP). The IL-36 receptor (IL-36R) antagonist spesolimab effectively manages GPP, rapidly controlling GPP flares and preventing their recurrence. A phase II trial of imsidolimab, a humanized IgG4 monoclonal antibody specifically binding IL-36R, demonstrated a rapid resolution of pustular eruptions in GPP patients.1